ライフサイエンスコーパス: AAV

1 AAV has emerged as the vector of choice for gene deliver

2 AAV status was associated with a 60% reduction in odds o

3 AAV-hepcidin injected eyes had increased ferritin immuno

4 AAV-NT mice also expressed increased levels of E-cadheri

5 argeted adenoassociated virus serotype DJ/8 (AAV-DJ/8) in BTBR wild-type and BTBR Lep(ob) mice.

6 biopsy specimens from 44 patients with acute AAV had more mast cells in the interstitium, which corre

7 Hippocampal antibody levels achieved after AAV delivery were approximately 50-fold more than those

8 ecovery after SH and enhanced recovery after AAV-TrkB treatment.

9 Eight weeks after AAV injection, inhibition of activin A and activin B sig

10 toms and complications are less common among AAV pertussis patients, demonstrating that the positive

11 anistic roles in assembly might differ among AAV serotypes remains uncharacterized.

12 ly processes are surprisingly distinct among AAV serotypes 1 to 12.

13 by evolving murine antigenic epitopes on an AAV serotype 1 capsid template can evade NAbs without co

14 We packaged an AAV genome encoding green fluorescent protein (GFP) into

15 ly cross the blood-brain barrier, we used an AAV vector to deliver antibody directly to the hippocamp

16 ored PHF1 compared with mice treated with an AAV-IgG control vector.

17 in PD mice injected intramuscularly with an AAV-TFEB vector.

18 g) receptor hM4Di in sensorimotor cortex and AAV-expressing Cre in C7/C8 dorsolateral funiculus.

19 Here, we describe AAV-PHP.eB and AAV-PHP.S, capsids that efficiently transduce the centra

20 or templates, we show that combining RNP and AAV donor delivery increases the efficiency of gene addi

21 yploid AAV vectors can be generated from any AAV serotype, whether natural, rational, library derived

22 This approach can be applied to any AAV strain to evade NAbs in prospective patients for hum

23 Together with an intersectional approach, AAV-mediated anterograde transsynaptic tagging can categ

24 ane protein, KIAA0319L (denoted hereafter as AAV receptor (AAVR)).

25 r GLP-1R-mediated effects on energy balance, AAV-GLP-1R was injected into the NTS to examine the role

26 Because AAV vectors are already used for liver-directed human ge

27 added insight into the possible link between AAV integration events and the multifactorial pathogenes

28 d hypertrophy comparable to that achieved by AAV:beta2-AR.

29 Rescue of the STGD1 phenotype by AAV-CRRY gene therapy suggests that complement attack on

30 ctor transduction kinetics, using a chimeric AAV capsid, were determined in rabbits.

31 2161380), the study drug (self-complementary AAV [scAAV]2(Y444,500,730F)-P1ND4v2) was intravitreally

32 Self-complementary AAV cassettes containing codon optimized HLA-G1 (transme

33 The self-complementary AAV vector preparation appears to contain particles with

34 ons of HBV delivered by a self-complementary AAV vector showed better antiviral effects than single s

35 both single-stranded and self-complementary AAV vectors indicate that the genomes are largely packag

36 he central fovea of BCM patients to consider AAV-mediated gene augmentation therapy.

37 To overcome this obstacle, we constructed AAV vectors carrying the channelrhodopsin-2 (ChR2) gene

38 reporter protein (NpHR-mCherry) or a control AAV (mCherry) plus optic fiber implants into the lOFC (E

39 served in diabetic animals receiving control AAV injections.

40 a substantial improvement over conventional AAV vectors.

41 he potential of CREATE to produce customized AAV vectors for biomedical applications.

42 me receptor.IMPORTANCE Over the past decade, AAV vectors have emerged as leading gene delivery tools

43 Here, we further define AAV-AAVR interactions, genetically and biochemically, an

44 ing on retinal transduction by Ivt-delivered AAVs.

45 Here, we describe AAV-PHP.eB and AAV-PHP.S, capsids that efficiently trans

46 We used a "designer" AAV, AAV2/Anc80L65, in which the main capsid proteins ap

47 levels in the germ line (Vgf+/-) or in dHc (AAV-Cre-injected floxed mice) showed increased susceptib

48 r, through the investigation of 12 different AAV serotypes (AAV1 to -12), we find that AAP is not an

49 AAVR as a critical entry receptor, different AAV serotypes have evolved distinctive interactions with

50 y and biochemically, and show that different AAV serotypes have discrete interactions with the Ig-lik

51 The disparate AAV phenotypes indicate that HS binding, while critical

52 ted viral particles to generate two distinct AAV interactomes, and identify several functional classe

53 strophic mdx(4cv) mice using single and dual AAV vector delivery of a muscle-specific Cas9 cassette t

54 ral vector expressing Flag-micro-dystrophin (AAV-muDys) to young adult mdx mice.

55 Empty AAV capsids are intrinsically heterogeneous, and capsids

56 ploration of effective strategies to enhance AAV transduction and escape from Nab activity is still i

57 ne deacetylase 4 (HDAC4) expression enhanced AAV transduction.

58 in I (EerI) as a novel reagent that enhances AAV transduction.

59 FVII-G96E dogs received escalating AAV doses (2E11 to 4.95E13 vector genomes [vg] per kg).

60 some-associated adeno-associated virus, (exo-AAV) enabled broad retinal targeting following intravitr

61 Finally, AAV-shRNA-mediated knockdown of VTA GLP-1 receptors was

62 By contrast, optogenetic activation or focal AAV-Cre-mediated knockdown of striatopallidal A(2A)R in

63 opment in oncology and future directions for AAV in this field.

64 of this association and the implications for AAV vector safety.

65 at newborn liver may be an ideal setting for AAV-mediated gene correction using CRISPR-Cas9.

66 From AAV injections into 42 neocortical and allocortical area

67 have shown the compatibility of capsids from AAV serotypes and homology of recognition sites of AAV N

68 AAV-2/9 containing a CMV-driven MMP-3 gene (AAV-MMP-3) into wild type mice resulted in efficient tra

69 aspects of the AAV life cycle, including how AAV interacts with host cellular factors to facilitate i

70 n more detail is important to understand how AAV engages with its cellular receptor and how the recep

71 The recently identified AAV receptor (AAVR) is a key host receptor for multiple

72 Liver-targeted IDOL-AAV-DJ/8 increased plasma LDL cholesterol compared with

73 T2 mice using imaging, immunohistochemistry, AAV-FLEX-GFP microinjections, and crosses to RiboTag, Ai

74 Most importantly, AAV-mediated expression of MMP-3 increased outflow facil

75 ormation is important for efforts to improve AAV genome packaging and will also inform the engineerin

76 t the importance of the nucleolus and AAP in AAV assembly and show the heterogeneous nature of the as

77 Consistently, in AAV-NT mice, hepatic levels of active STAT3 and NFkappaB

78 were increased in ZIP8-LSKO and decreased in AAV-ZIP8 mice.

79 ession was approximately fourfold greater in AAV-TrkB- vs. AAV-GFP-treated SH animals (P < 0.004) and

80 ance between tolerance and immunogenicity in AAV vector-mediated gene transfer are not fully understo

81 ment pathway (AP) was recently implicated in AAV, and C5a inhibition is currently being tested in cli

82 ipsilateral diaphragm activity increased in AAV-TrkB-treated (9/9) compared with untreated (3/5) or

83 and exhibit a novel therapeutic strategy in AAV.

84 d provides a potential therapeutic target in AAV.

85 We now show that in AAV-NT mice, the signaling pathways of the CR mediators,

86 can explain the absence of hepatic tumors in AAV-NT mice.

87 A number of nonenveloped viruses, including AAV, carry proteases that are needed for capsid maturati

88 following a corneal intrastromal injection, AAV vector transduction kinetics, using a chimeric AAV c

89 One lead AAV variant generated by combining multiple evolved anti

90 Here we show that post-lesional AAV-assisted co-expression of two soluble proteins, name

91 Better understanding of neutrophil-mediated AAV disease mechanisms may reveal novel treatment strate

92 ted virus (rAAV) vector-treated GSD-Ia mice (AAV-NT mice) expressing a wide range (0.9-63%) of normal

93 o previous work on Alzheimer's mouse models, AAV-Gfa2-VIVIT had no effects on the levels of GFAP and

94 ing a short hairpin RNA against Homer1 mRNA (AAV-shHomer1).

95 ransduction of vectors derived from multiple AAV serotypes, including the evolutionarily distant sero

96 esent a platform that integrates multiplexed AAV/Cas9-mediated homology-directed repair (HDR) with DN

97 partment, for disease induction using murine AAV models and in human kidney biopsies.

98 t behaviors, respectively, while dHc- or NAc-AAV-VGF overexpression induced opposite outcomes.

99 enic footprints that do not exist in natural AAV isolates.

100 Nevertheless, AAVs that provide efficient transduction across specific

101 AVs is limited, prompting a search for novel AAV capsids with desired characteristics.

102 he tropism repertoire of naturally occurring AAVs is limited, prompting a search for novel AAV capsid

103 The ability of AAV to cotransduce HSV-1-infected neurons in both the mo

104 ene therapy; however, fundamental aspects of AAV's capsid assembly remain poorly characterized.

105 et by intravitreal delivery, but delivery of AAV by this route results in poor transduction outcomes.

106 Subretinal delivery of AAV serotype 2 (AAV2) and its heparan sulfate (HS)-bindi

107 sented here provide the first description of AAV vectors transducing neurons following delivery at th

108 ibrillary tangles following a single dose of AAV-vectored PHF1 compared with mice treated with an AAV

109 riodic induction, via use of an eye drop, of AAV-mediated secretion of MMP-3 into AH could have thera

110 can be avoided by enhancing the efficacy of AAV vectors in hepatocytes.

111 Further, the efficacy of AAV-Clrn1 vector was significantly attenuated, revealing

112 greatly improved transduction efficiency of AAV vectors in human and mouse hepatocytes independent o

113 ging and will also inform the engineering of AAV capsid variants for improved tropism, specific tissu

114 s from parental serotypes for enhancement of AAV transduction and evasion of Nab recognition without

115 ing cell lines and the directed evolution of AAV capsids.IMPORTANCE We first report that an autonomou

116 in KO-TgAC1 mice with a single injection of AAV-Clrn1-UTR vector showed correlative preservation of

117 After region-specific viral injections of AAV-GFP or AAV-CRE in CREB(loxP/loxP) animals, behaviora

118 exogenous MMP-3.Intracameral inoculation of AAV-2/9 containing a CMV-driven MMP-3 gene (AAV-MMP-3) i

119 e-treatment allowed efficient maintenance of AAV genomes in mdx muscles and enhanced the AAV-U7 thera

120 AAP) sheds new light on this crucial part of AAV biology and vector production.

121 with greater accumulation and penetration of AAV in the retina.

122 This review summarizes the progress of AAV-mediated gene therapy for the hemophilias, along wit

123 rovide evidence that antibody recognition of AAV capsids is conserved across species.

124 This effect was preceded by sequestration of AAV within enlarged vesicles that were dispersed through

125 Although some serotypes of AAV are known to have nerve tropism, whether AAV can dis

126 rotypes and homology of recognition sites of AAV Nab located on different capsid subunits from one vi

127 We also discuss the current status of AAV clinical development in oncology and future directio

128 y of the dystrophic myofibers at the time of AAV-U7 injection, mdx muscles were pre-treated with a si

129 Our results demonstrate the utility of AAV-L7-ChR2 for revealing the contributions of Purkinje

130 of striatal neurons, while 1 x 10(12) vg of AAV-PHP.S transduced 82% of dorsal root ganglion neurons

131 tration of 1 x 10(11) vector genomes (vg) of AAV-PHP.eB transduced 69% of cortical and 55% of striata

132 cell response determining the efficiency of AAVs intracellular processing in hepatocytes and thus th

133 and increased visual chromophore in 1-y-old AAV-CRRY-treated STGD1 mice.

134 acterized the impact of hepatic autophagy on AAV infection.

135 Previous studies on AAV serotype 2 (AAV2) showed that assembly takes place i

136 y recognition sites or antigenic hotspots on AAVs and other related parvoviruses might be evolutionar

137 eated (9/9) compared with untreated (3/5) or AAV-GFP-treated (4/10; P < 0.027) animals.

138 gion-specific viral injections of AAV-GFP or AAV-CRE in CREB(loxP/loxP) animals, behavioral testing m

139 ndent of the transgene, driving promoter, or AAV serotype and was subsequently confirmed in vivo.

140 Furthermore, other AAV serotypes, including AAV1 and -8, require a combinat

141 uate if HS binding could be applied to other AAV serotypes to enhance their transduction, AAV1 and AA

142 f binding from molar excess of overexpressed AAV-delivered mAgrin.

143 uced higher transduction than their parental AAV vectors (2- to 9-fold over AAV2), with the highest o

144 In particular, AAV receptors contribute significantly to AAV vector tra

145 Polyploid AAV vectors can be generated from any AAV serotype, whet

146 e control enhanced green fluorescent protein AAV-DJ/8.

147 ome may be useful for generating recombinant AAV-packaging cell lines and the directed evolution of A

148 or suppression by food intake), recombinant AAV-mediated transgene expression was markedly reduced,

149 lications for the improvement of recombinant AAV production in HEK293 cells and cell types that do no

150 We further show that recombinant AAV serotype 1 (rAAV1) transduces ECs of pathologic vess

151 ne therapy clinical trials using recombinant AAV vectors.

152 Specifically, EerI treatment redirected AAV particles toward large vesicles positive for late en

153 (AAV) vector producing a short hairpin RNA (AAV.sh.p11).

154 anial and intrathecal injections of the same AAV vector were combined.

155 ld be co-delivered to TG neurons by separate AAV vectors.

156 d virus containing the CRRY coding sequence (AAV-CRRY) into the subretinal space of 4-wk-old Abca4(-/

157 with stereotaxic injection of 5-HT2CR shRNA AAV vector decreased vocalizations and anxiety- and depr

158 bition of c-Fos using photoreceptor-specific AAV (adeno-associated virus)-hRK (human rhodopsin kinase

159 Biodistribution analyses suggested AAV vectors persisted only in the trauma-induced corneas

160 alphaKL-null mice with sustained AAV-cKL expression had a 74%-78% reduction in aorta mine

161 lifespan of the Npc1-/- mice after systemic AAV gene delivery.

162 ng ligands on the viral capsid can re-target AAVs to new cell types, but limited sites have been iden

163 Our results demonstrate that AAV-mediated muscle-specific gene editing has significan

164 We demonstrated that AAV vectors of serotypes 1, 7, 8, and 9 trafficked from

165 We found that AAV induced mammalian target of rapamycin (mTOR)-depende

166 We also show that AAV delivered M-opsin localizes in the dorsal cone outer

167 The AAV treatment markedly reduces SLN expression, attenuate

168 CD8(+) T-cell responses against the AAV capsid protein can, however, affect therapeutic effi

169 cid substitution can significantly alter the AAV capsid integrity to the extent of reducing its stabi

170 e, we further biochemically characterize the AAV-AAVR interaction and define the domains within the e

171 Defining the AAV-AAVR interface in more detail is important to unders

172 lity displayed by Rep68 and Rep78 during the AAV life cycle.

173 AAV genomes in mdx muscles and enhanced the AAV-U7 therapy effect with a ten-fold increase of the pr

174 tes a strategy for inserting motifs into the AAV capsid without compromising viral titer or infectivi

175 ite-specific tetracysteine sequence into the AAV serotype 9 (AAV9) capsid, to permit labelling of vir

176 in the 163-nt common insertion region of the AAV genome, which has been implicated in the dysregulati

177 However, fundamental aspects of the AAV life cycle, including how AAV interacts with host ce

178 chment of receptor-targeting agents onto the AAV capsid holds potential to alter its tropism, but is

179 Neonate mice intravenously injected with the AAV-BR1-CAG-NEMO vector developed no hepatocellular carc

180 mice was fully rescued by treatment with the AAV-vectored PHF1 antibody.

181 us nature of the assembly process within the AAV family.

182 correlated with the loss of the therapeutic AAV genomes, probably due to alterations of the dystroph

183 type-specific promoters and enhancers, these AAVs enable efficient and targetable genetic modificatio

184 Thus, AAV- and CRISPR-Cas9-mediated HDR will be broadly useful

185 ociated refractive errors may be amenable to AAV gene therapy.

186 PPMO pre-treatment was also beneficial to AAV-mediated gene therapy with transfer of micro-dystrop

187 as Au040320(-/-) and Kiaa0319l(-/-)) mice to AAV infection.

188 two proteins from the interactomes prior to AAV transduction.

189 r, AAV receptors contribute significantly to AAV vector transduction efficiency and tropism.

190 For purity analysis, only 25 ng of total AAV capsid proteins (4.3 femtomole virus particles) were

191 virally encoded synaptic anterograde tracer, AAV-SynaptoTag, followed by 3D reconstruction of the cor

192 eral infusions of a retrogradely transported AAV vector expressing Cre recombinase (Retro-Cre-GFP) in

193 We treated AAV-TBG-Cre; Rosa(YFP) mice with diethylnitrosamine (DEN

194 Importantly, treating AAV-NT mice with a sirtuin-1 inhibitor markedly reversed

195 Here we intravenously infuse two AAVs, one expressing Cas9 and the other expressing a gui

196 gene as well as for the rescue of wild-type AAV genomes from tissues during directed evolution in th

197 nown to prevent degradation of ubiquitinated AAV capsids, thereby leading to increased nuclear accumu

198 Unexpectedly, AAV-CRRY-treated STGD1 mice also showed reduced accumula

199 A related approach uses AAV vectors to edit specific regions of the DMD gene usi

200 Using AAV vectors to deliver antibodies like PHF1 directly to

201 outcome of liver-directed gene therapy using AAV vectors and showed in a proof-of-principle study how

202 Rb1, which were subsequently validated using AAV minipools.

203 ge-appropriate number of pertussis vaccines (AAV) (for persons aged >/=3 months) was associated with

204 One variant, AAV-PHP.B, transfers genes throughout the CNS with an ef

205 asmic antibody (ANCA)-associated vasculitis (AAV) constitutes life-threatening autoimmune diseases af

206 ANCA-associated vasculitis (AAV) is a highly inflammatory condition in which ANCA-ac

207 peroxidase (MPO)-ANCA-associated vasculitis (AAV) show mast cells degranulate, thus enhancing injury

208 scles with an adeno-associated viral vector (AAV) encoding human Neurotrophin-3 at a clinically-feasi

209 of the adeno-associated virus (AAV) vector, AAV-BR1-CAG-NEMO, delivering the Nemo gene to the brain

210 injection of adeno-associated viral vectors (AAVs) encoding ligand-specific antagonists into the tibi

211 on of striatal GDNF levels in adult mice via AAV-Cre delivery.

212 novel combinatorial adeno-associated viral (AAV) gene therapy by expressing DAT selectively in DA ne

213 /Mfrp (rd6) mice via adeno-associated viral (AAV) gene therapy.

214 ed a single-stranded adeno-associated viral (AAV) vector consisting of a bioengineered capsid, liver-

215 s of a Cre-dependent adeno-associated viral (AAV) vector expressing enhanced halorhodopsin 3.0 fused

216 Use of adeno-associated viral (AAV) vectors for liver-directed gene therapy has shown c

217 therapies utilizing adeno-associated viral (AAV) vectors hold great promise for treating Duchenne mu

218 nal overexpression of adenoassociated virus (AAV)-ACE2 prevents or reverses diabetic retinopathy.

219 , in combination with adenoassociated virus (AAV)-mediated overexpression of human alpha-syn, at leve

220 aneous or enhanced by adenoassociated virus (AAV)-mediated upregulation of TrkB receptor expression,

221 pplied STN-DBS in an adeno-associated virus (AAV) 1/2-driven human mutated A53T alpha-synuclein (aSyn

222 electroporation and adeno-associated virus (AAV) 6 delivery of donor constructs in human HSPCs appro

223 x:utr (-/-) mice via adeno-associated virus (AAV) 9-mediated RNA interference.

224 e Rep68 protein from adeno-associated virus (AAV) combines a DNA binding and endonuclease domain with

225 e model of CHB using adeno-associated virus (AAV) delivery.

226 rally recombinogenic adeno-associated virus (AAV) donor vectors enables site-specific gene insertion

227 elivered recombinant adeno-associated virus (AAV) encoding Abeta42 and Abeta40 peptides fused to BRI2

228 Adeno-associated virus (AAV) entry is determined by its interactions with specif

229 Stable delivery of adeno-associated virus (AAV) expressing cKL to diabetic endothelial nitric oxide

230 eal vascularization, adeno-associated virus (AAV) gene therapy, exploiting a natural immune tolerance

231 administration of an adeno-associated virus (AAV) gene transfer vector significantly prevented pathol

232 SPR-Cas9 delivery by adeno-associated virus (AAV) holds promise for gene therapy but faces critical b

233 livery of mAgrin via adeno-associated virus (AAV) into FKRP mutant mice was unable to improve dystrop

234 Adeno-associated virus (AAV) is a replication-deficient parvovirus that is exten

235 Adeno-associated virus (AAV) is frequently used to manipulate gene expression in

236 ting viruses such as adeno-associated virus (AAV) is not optimal in this setting because the noninteg

237 the human parvovirus adeno-associated virus (AAV) is orchestrated by four Rep proteins.

238 recently discovered adeno-associated virus (AAV) protein that promotes capsid assembly and provides

239 Many adeno-associated virus (AAV) serotypes efficiently transduce the retina when del

240 r purity analysis of adeno-associated virus (AAV) therapeutic products of different serotypes and tra

241 bility to target the adeno-associated virus (AAV) to specific types of cells, by altering the cell-su

242 ously shown that the adeno-associated virus (AAV) variant, ShH10, transduces Muller cells in the Dp71

243 passionate use of an adeno-associated virus (AAV) vector containing the human AADC gene (AAV2-hAADC)

244 atum, we injected an adeno-associated virus (AAV) vector producing a short hairpin RNA (AAV.sh.p11).

245 d function following adeno-associated virus (AAV) vector transduction of MPS1 patient fibroblasts.

246 ravenous dose of the adeno-associated virus (AAV) vector, AAV-BR1-CAG-NEMO, delivering the Nemo gene

247 from a set of other adeno-associated virus (AAV) vectors as a potent vector for the cochlear cell ta

248 athway in rats using adeno-associated virus (AAV) vectors expressing the astrocyte-specific promoter

249 we review the use of adeno-associated virus (AAV) vectors for delivery of HIV bNAbs and antibody-like

250 We investigated adeno-associated virus (AAV) vectors for gene delivery to the TG after intraderm

251 in gene therapy with adeno-associated virus (AAV) vectors have been the object of almost two decades

252 Adeno-associated virus (AAV) vectors have been used successfully in clinical tri

253 Adeno-associated virus (AAV) vectors have made great progress in their use for g

254 2-fold interface of adeno-associated virus (AAV) was defective for transcription of the packaged gen

255 We combined the adeno-associated virus (AAV) with the Cre-loxP site-specific recombination syste

256 y into the capsid of adeno-associated virus (AAV), a vector that has shown promise in neuroscience re

257 ly investigated with adeno-associated virus (AAV), an anterograde viral tracer.

258 ds for radiolabeling adeno-associated virus (AAV), one of the most commonly used viral vectors for ge

259 age the library into adeno-associated virus (AAV), thereby allowing delivery to target organs in vivo

260 Adeno-associated virus (AAV)-Cre-mediated Vgf ablation in floxed VGF mice, in do

261 a lineage-specific, adeno-associated virus (AAV)-derived endogenous viral element (mAAV-EVE1) found

262 fically by injecting adeno-associated virus (AAV)-expressing Cre-dependent DREADD (designer receptor

263 Adeno-associated virus (AAV)-hepcidin was injected into the eyes of hepcidin kno

264 ort that a system of adeno-associated virus (AAV)-mediated clustered regularly interspaced short pali

265 ng approach in which adeno-associated virus (AAV)-mediated CRISPR/Cas9 delivery to postmitotic photor

266 ted expression using adeno-associated virus (AAV)-mediated gene delivery.

267 We use adeno-associated virus (AAV)-mediated gene editing to knock in HLA-E genes at th

268 Adeno-associated virus (AAV)-mediated gene therapy is currently being pursued as

269 tential of naked and adeno-associated virus (AAV)-packaged AONs in vitro and in vivo In both cases, A

270 n restoration during adeno-associated virus (AAV)-U7-mediated exon-skipping therapy was shown to decr

271 dministration of the adeno-associated virus (AAV)-vectored anti-phospho-tau antibody PHF1 to P301S ta

272 fficiently regulated adeno-associated virus (AAV)-vectored transgene expression in cultured mammalian

273 deficient mice using adeno-associated virus (AAV).

274 donor template with adeno-associated virus (AAV).

275 activation by using adeno-associated virus (AAV)9 gene therapy vectors carrying the telomerase Tert

276 we developed a novel adeno-associated virus (AAV-GLP-1R) that utilizes short hairpin RNA to chronical

277 croinjection of a Cre-inducible ErbB4 virus (AAV-ErbB4.DIO) into the mesencephalon of TH-Cre;ErbB4(f/

278 gative, deacetylase-dead point mutant virus (AAV-HDAC3(Y298H)-v5), we found that selectively blocking

279 The adeno-associated viruses (AAV) are promising therapeutic gene delivery vectors and

280 ase of recombinant adeno-associated viruses (AAV), proteasome inhibitors are known to prevent degrada

281 Adeno-associated viruses (AAVs) are attractive gene therapy vectors due to their l

282 Adeno-associated viruses (AAVs) are commonly used for in vivo gene transfer.

283 Recombinant adeno-associated viruses (AAVs) are promising vectors for human gene therapy.

284 ies (NAbs) against adeno-associated viruses (AAVs) pose a major, unresolved challenge that restricts

285 nd into the mouse cerebral cortex by in vivo AAV injection.

286 roximately fourfold greater in AAV-TrkB- vs. AAV-GFP-treated SH animals (P < 0.004) and in animals di

287 tussis patients aged >/=3 months, 77.6% were AAV.

288 s expected in control lesioned mice, whereas AAV.sh.p11 mice remained at or near normal baseline.

289 AAV are known to have nerve tropism, whether AAV can distribute to sensory nerves that innervate the

290 to the eyes of hepcidin knockout mice, while AAV-lacZ was injected into the contralateral eyes as a c

291 ogy triggered by fibrils in combination with AAV-mediated overexpression of alpha-syn reproduced many

292 for unifying nuclease protein delivery with AAV donor vectors for homology-directed genome editing.

293 ced in BDNF floxed mice injected in dHc with AAV-Cre, and in NBQX- and rapamycin-pretreated wild-type

294 his article, we describe our experience with AAV viral vector delivery system, that allows us to opti

295 Rats were injected intrapleurally with AAV expressing TrkB or GFP 3 weeks before SH.

296 we show that hepatic disruption of Ldlr with AAV-CRISPR results in severe hypercholesterolemia and at

297 Behaviorally, KO mice as well as mice with AAV-mediated deletion of CK2alpha in the PFC show a robu

298 helial phospho-p65 staining in patients with AAV indicated that NF-kappaB is activated in human NCGN

299 imilarly, coadministration of rapamycin with AAV vectors resulted in markedly enhanced expression of

300 of human ZIP8 (adeno-associated virus-ZIP8 [AAV-ZIP8]) resulted in increased tissue and whole blood